Skip to content

Solventum SOLV Pre-tax stock-based compensation cost

Pre-tax stock-based compensation cost at other companies

Medline, Inc.
 logo
Medline, Inc. MDLN
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$2.0B-3.0%
Gross profit$1.1B-1.5%
Operating income$81.0M-46.7%
Net income$13.0M-90.5%
EPS (diluted)$0.07-91.0%

Balance sheet

See full
Cash & equivalents$561.0M+5.1%
Total debt$5.8B-26.8%
Total equity$5.0B+52.3%
Total assets$14.1B-3.0%

Cash flow

See full
Operating cash flow-$189.0M-752%
CapEx$84.0M-22.9%
Free cash flow-$273.0M-241%

Valuation

See full
Market cap$13.06B-13.9%
Enterprise value$18.29B-19.4%
P/E9.1×-30.9×
P/S1.6×-0.2×

Profitability

See full
Gross margin53.7%-0.9pp
Operating margin25.5%+15.8pp
Net margin17.3%+12.8pp
FCF margin4.6%-13.9pp

Returns & leverage

See full
Return on equity34.8%+24.1pp
Debt / equity1.2×-1.3×
Current ratio1.1×-0.1×

Where this comes from

Reported directly by Solventum in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Solventum’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solventum's pre-tax stock-based compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solventum's pre-tax stock-based compensation cost?
Solventum (SOLV) reported pre-tax stock-based compensation cost of $51M in Q1 2026.
How has Solventum's pre-tax stock-based compensation cost changed year-over-year?
Solventum's pre-tax stock-based compensation cost increased by 4.1% year-over-year, from $49M to $51M.